Abstract
Bone metastases represent a critical factor contributing to illness and mortality among men diagnosed with prostate cancer. This study evaluates the therapeutic effectiveness of denosumab, a fully human monoclonal antibody targeting RANKL, in comparison to zoledronic acid for reducing the occurrence of such metastases or mortality in these patients. The investigation utilized a Cox proportional hazards model to assess bone-metastasis-free survival, factoring in variables such as chemotherapy use. Kaplan-Meier survival curves and hazard ratios (HRs) were employed to evaluate treatment differences. Results indicated that the antibody extended survival by a median of 29.97 months over its comparator. Moreover, it postponed the initial onset of metastases and improved survival outcomes. It outperformed the alternative treatment in minimizing skeletal complications and holds potential as an innovative option for men in this condition.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call